Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 36-45 , January 2010

Another treatment gap: Restarting secondary prevention medications: The Women's Health Initiative

  • Jennifer G. Robinson, MD, MPH

      Affiliations

    • Department of Medicine, 200 Hawkins Drive SE 21C GH, University of Iowa, Iowa City, IA 52242 USA
    • Department of Epidemiology, 200 Hawkins Drive SE 21C GH, University of Iowa, Iowa City, IA 52242 USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Robert Wallace, MD

      Affiliations

    • Department of Epidemiology, 200 Hawkins Drive SE 21C GH, University of Iowa, Iowa City, IA 52242 USA
    • ,
  • Monika M. Safford, MD

      Affiliations

    • Deep South Center on Effectiveness at the Birmingham VA Medical Center and the University of Alabama, Birmingham, AL, USA
    • ,
  • Mary Pettinger, MS

      Affiliations

    • Fred Hutchinson Cancer Center, Seattle, WA, USA
    • ,
  • Barbara Cochrane, PhD, RN

      Affiliations

    • University of Washington, Seattle, WA, USA
    • ,
  • Marcia G. Ko, MD

      Affiliations

    • Division of Women's Health, Mayo Clinic, Scottsdale, AZ, USA
    • ,
  • Mary Jo O'Sullivan, MD

      Affiliations

    • University of Miami, Miller School of Medicine, Miami, FL, USA
    • ,
  • Kamal Masaki, MD

      Affiliations

    • Department of Geriatric Medicine, University of Hawaii, Manoa, HI
    • John A. Burns School of Medicine and School of Public Health, University of Hawaii, Manoa, HI; for the Women's Health Initiative Investigators
    • ,
  • Helen Petrovich, MD

      Affiliations

    • John A. Burns School of Medicine and School of Public Health, University of Hawaii, Manoa, HI; for the Women's Health Initiative Investigators

Received 6 November 2009 ,Accepted 18 December 2009.

References 

  1. Robinson JG, Maheshwari N. A “poly-portfolio” for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol. 2005;95:373–378
  2. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51:1247–1254
  3. Smith JSC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–2139
  4. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–186
  5. Agency for Healthcare Research and Quality. National Healthcare Quality Report. Effectiveness: Heart Disease. Rockville, MD: US Department of Health and Human Services; 2003;59–74
  6. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA. 2001;286:1732–1739
  7. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842–1847
  8. Albert NM, Birtcher KK, Cannon CP, et al. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines Database). Am J Cardiol. 2008;101:1242–1246
  9. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13:S78–S86
  10. Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative Dietary Modification Trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13:S87–S97
  11. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trials and observational study. Control Clin Trials. 1998;19:61–109
  12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  13. Hsia J, Langer RD, Manson JE, et al. Women's Health Initiative Investigators Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357–365
  14. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative randomized controlled dietary modification trial. JAMA. 2006;295:655–666
  15. Curb JD, Mctiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13:S122–S128
  16. Setoguchi S, Solomon DH, Levin R, Winkelmayer WC. Gender differences in the management and prognosis of myocardial infarction among patients ≥65 years of age. Am J Cardiol. 2008;101:1531–1536
  17. Jani SM, Montoye C, Mehta R, et al. American College of Cardiology Foundation Guidelines Applied in Practice Steering Committee Sex differences in the application of evidence-based therapies for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice Projects in Michigan. Arch Intern Med. 2006;166:1164–1170
  18. Spencer FA, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Decade-long changes in the use of combination evidence-based medical therapy at discharge for patients surviving acute myocardial infarction. Am Heart J. 2005;150:838–844
  19. Vaccarino V, Rathore SS, Wenger NK, et al. National Registry of Myocardial Infarction I Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med. 2005;353:671–682
  20. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847–852
  21. Newby LK, Allen LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–212
  22. Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: A national survey 1 year before the Medicare Drug Benefit. Arch Intern Med. 2006;166:1829–1835

PII: S1933-2874(09)00449-8

doi: 10.1016/j.jacl.2009.12.006

Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 36-45 , January 2010

Article Tools

* Image Usage & Resolution